CSIMarket
 


Organovo Holdings Inc   (ONVO)
Other Ticker:  
 

Organovo Holdings Inc 's Working Capital Ratio

ONVO's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2023, Working Capital Ratio deteriorated to 5.19 below Organovo Holdings Inc 's average Working Capital Ratio.

Within Biotechnology & Pharmaceuticals industry 89 other companies have achieved higher Working Capital Ratio than Organovo Holdings Inc in second quarter 2023. While Working Capital Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 791 to 914.

Explain Working Capital Ratio
How much in Current Assets ONVO´s has?
What is the value of ONVO´s Current Liabilities?


ONVO Working Capital Ratio (Sep 30 2023)
II. Quarter
(Jun 30 2023)
I. Quarter
(Mar 31 2023)
IV. Quarter
(Dec 31 2022)
III. Quarter
(Sep 30 2022)
II. Quarter
Y / Y Current Liabilities Change 15.19 % 38.07 % 165.44 % -31.41 % -17.07 %
Y / Y Current Assets Change -65.94 % -56.54 % -42.27 % -30.66 % -28.99 %
Working Capital Ratio MRQ 5.19 6.61 4.64 15.71 17.54
ONVO's Total Ranking # 914 # 791 # 1211 # 373 # 367
Seq. Current Liabilities Change -9.6 % -51.78 % 166.79 % -0.94 % 8.35 %
Seq. Current Assets Change -29.06 % -31.4 % -21.13 % -11.26 % -9.48 %



Working Capital Ratio second quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 90
Healthcare Sector # 432
Overall Market # 914


Working Capital Ratio Statistics
High Average Low
53.26 15.36 0.04
(Mar 31 2021)   (Dec 31 2011)




Financial Statements
Organovo Holdings Inc 's Current Liabilities $ 2 Millions Visit ONVO's Balance sheet
Organovo Holdings Inc 's Current Assets $ 8 Millions Visit ONVO's Balance sheet
Source of ONVO's Sales Visit ONVO's Sales by Geography


Cumulative Organovo Holdings Inc 's Working Capital Ratio

ONVO's Working Capital Ratio for the trailling 12 Months

ONVO Working Capital Ratio

(Sep 30 2023)
II. Quarter
(Jun 30 2023)
I. Quarter
(Mar 31 2023)
IV. Quarter
(Dec 31 2022)
III. Quarter
(Sep 30 2022)
II. Quarter
Y / Y Current Liabilities TTM Growth 15.19 % 38.07 % 165.44 % -31.41 % -17.07 %
Y / Y Current Assets TTM Growth -65.94 % -56.54 % -42.27 % -30.66 % -28.99 %
Working Capital Ratio TTM 6.97 9.1 11.65 18.86 18.48
Total Ranking TTM # 3792 # 2565 # 3942 # 12 # 3838
Seq. Current Liabilities TTM Growth -9.6 % -51.78 % 166.79 % -0.94 % 8.35 %
Seq. Current Assets TTM Growth -29.06 % -31.4 % -21.13 % -11.26 % -9.48 %


On the trailing twelve months basis Due to decrease in Current Liabilities in the II Quarter 2023 to $1.60 millions, cumulative Working Capital Ratio decreased to 6.97 below the Organovo Holdings Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 163 other companies have achieved higher Working Capital Ratio than Organovo Holdings Inc . While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2023 from 2565 to 3792.

Explain Working Capital Ratio
How much in Current Assets ONVO´s has?
What is the value of ONVO´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 164
Healthcare Sector # 996
Within the Market # 3792


trailing twelve months Working Capital Ratio Statistics
High Average Low
36.14 16 6.97
(Jun 30 2021)   (Sep 30 2023)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Aura Biosciences Inc   14.13 $ 153.888  Millions$ 10.894  Millions
Vor Biopharma Inc   14.12 $ 164.438  Millions$ 11.645  Millions
Pharmacyte Biotech Inc   14.08 $ 73.748  Millions$ 5.240  Millions
Vigil Neuroscience Inc   13.79 $ 139.847  Millions$ 10.142  Millions
Molecular Partners Ag  13.35 $ 192.459  Millions$ 14.416  Millions
Anavex Life Sciences Corp   13.29 $ 154.386  Millions$ 11.617  Millions
Elevation Oncology inc   12.99 $ 98.797  Millions$ 7.607  Millions
Ambrx Biopharma Inc   12.80 $ 233.818  Millions$ 18.268  Millions
Replimune Group Inc   12.76 $ 508.175  Millions$ 39.832  Millions
Allogene Therapeutics inc   12.58 $ 473.454  Millions$ 37.636  Millions
Scholar Rock Holding Corp  11.70 $ 228.465  Millions$ 19.530  Millions
Kymera Therapeutics Inc   11.66 $ 375.694  Millions$ 32.219  Millions
Protara Therapeutics Inc   11.49 $ 77.813  Millions$ 6.775  Millions
Tarsus Pharmaceuticals Inc   11.15 $ 259.277  Millions$ 23.249  Millions
Inhibrx Inc   10.76 $ 363.297  Millions$ 33.760  Millions
Vir Biotechnology Inc   10.72 $ 1,769.176  Millions$ 165.050  Millions
Ikena Oncology Inc   10.41 $ 200.634  Millions$ 19.271  Millions
Invivyd Inc   10.08 $ 270.103  Millions$ 26.791  Millions
Cardiff Oncology inc   10.07 $ 83.905  Millions$ 8.330  Millions
Black Diamond Therapeutics Inc   9.76 $ 147.049  Millions$ 15.066  Millions
Argenx se  9.75 $ 4,123.737  Millions$ 422.993  Millions
Autolus Therapeutics Plc  9.62 $ 308.382  Millions$ 32.049  Millions
Biontech Se  9.43 $ 21,870.576  Millions$ 2,318.960  Millions
Solid Biosciences Inc   9.38 $ 148.346  Millions$ 15.816  Millions
Turnstone Biologics Corp   9.08 $ 118.835  Millions$ 13.081  Millions
Jasper Therapeutics Inc   8.84 $ 105.218  Millions$ 11.906  Millions
Fate Therapeutics Inc   8.81 $ 364.174  Millions$ 41.333  Millions
Springworks Therapeutics Inc   8.60 $ 432.383  Millions$ 50.283  Millions
Century Therapeutics inc   8.50 $ 173.703  Millions$ 20.435  Millions
Atyr Pharma Inc   8.33 $ 107.298  Millions$ 12.881  Millions

Date modified: 2023-11-12T10:41:49+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com